UPDATE: Teva scores a takeover talking point as Perrigo board rejects Mylan bid

In a statement, Perrigo's board said that Mylan's $29 billion bid "substantially undervalues" the firm. Advantage: Teva.

By Nicole Gray • April 21, 2015

What a Celgene stake in Mesoblast means for the stem cell firm's prospects

Celgene's purchase of 15.3 million shares of Mesoblast at $3.82 per share has substantially increased investor confidence.

By Nicole Gray • April 14, 2015

Ichor, J&J to collaborate in $85M hep B immunotherapy deal

The two companies are working together to develop and commercialize DNA-based vaccine therapies for treatment of chronic hepatitis B using Ichtor's platform.

By Nicole Gray • April 14, 2015

Mylan's $29B Perrigo bid seen as defensive play against M&A threat

Analysts suspect that the company's offer was a defense against a Teva takeover. 

By Nicole Gray • April 13, 2015

UPDATE: Mylan offers $29 billion to buy Perrigo, create generics powerhouse

The offer amounts to $205 per share, or about a 24% premium over Perrigo's closing price on Tuesday.

By Sy Mukherjee • April 8, 2015

Targacept merger in jeopardy as Pfizer ends deal with buyer Catalyst

Targacept's stock has crashed hard on the news.

By Nicole Gray • April 7, 2015

MorphoSys CEO stays bullish on cancer drug despite Celgene split

The company plans to move forward with the development of MOR202. 

By Nicole Gray • April 7, 2015

Juno, Novartis settle cancer patent spat for $12 million

Novartis will end up paying Juno Therapeutics a total of $12.25 million plus milestones for use of its chimeric receptor technology. 

By Nicole Gray • April 7, 2015

4 big biopharma deals we might see in 2015

Biopharma's already off to a historic start when it comes to deals in 2015. Here are four other ones we might see this year.

By Sy Mukherjee • April 6, 2015

Big bonus bonanza coming up at Actavis

The company's management team could see $101 million in bonuses.

By Nicole Gray • April 2, 2015

Partners wanted: Roche seeking collaborators in cancer immunotherapy

Severin Schwan, CEO of the Swiss drugmaker, is looking for collaborative research relationships to develop a range of immunooncology-based cancer drugs.

By Nicole Gray • April 2, 2015

Merck Serono and Intrexon initiate $941 million CAR-T deal

The CAR-T boom rages on.

By Nicole Gray • March 31, 2015

What UnitedHealth's $12.8B Catamaran deal means for pharma's pricing war

The marketing landscape is just going to get harder for the industry.

By Nicole Gray • March 31, 2015

The M&A train rolls on: Teva to buy American CNS drug maker for $3.2B

U.S.-based Auspex Pharma makes drugs for CNS disorders such as Huntington's and Tourette's.

By Sy Mukherjee • March 30, 2015

Celgene emerges as biotech partnering king of 2014

Under the leadership of George Golumbeski, the biotech forged 10 licensing deals last year.

By Nicole Gray • March 18, 2015

Allergan CEO Pyott heading for the exits as Actavis finalizes buyout

The times are changing over at Allergan.

By Nicole Gray • March 18, 2015

UPDATE: Valeant successfully fends off Endo, seals deal with Salix

Salix is walking away with even more cash from Valeant than it expected, spurred by a last-minute poaching bid from Endo.

By Sy Mukherjee • March 16, 2015

Bill & Melinda Gates Foundation bets big on CureVac's mRNA platform

The foundation is investing $52 million in the Germany-based company.

By Nicole Gray • March 13, 2015

Zogenix selling painkiller Zohydro to Pernix in huge deal

Pernix Therapeutics could end up paying a total of $383.5 million for the opioid painkiller Zohydro.

By Nicole Gray • March 12, 2015

Concordia acquiring Covis assets for $1.2 billion

The Canada-based company is buying 18 branded and authorized generic products from the privately held Covis Pharmaceuticals. 

By Nicole Gray • March 11, 2015

Why CNS drug maker Acadia's shares soared on Tuesday

Rumors of a buy-out have been propelled by Acadia canceling two investor's conferences in a row, sending its stock soaring.

By Nicole Gray • March 11, 2015

Ackman becomes Valeant's 5th largest shareholder with $3.3B gamble

With Ackman's latest investment, Pershing Square now owns 4.9% of Valeant.

By Nicole Gray • March 9, 2015

AbbVie beats out J&J, will buy Pharmacyclics for $21B to boost cancer pipeline

With lower Humira sales on the horizon, AbbVie will get a big boost from Pharmacyclics' expected cancer blockbuster Imbruvica.

By Sy Mukherjee • March 5, 2015

The post-acquisition cuts begin: Valeant lays off 77 Dendreon employees

As of February 23, Valeant started laying off the 77 Dendreon employees slated for termination after the now-defunct company's $495 million acquisition by Valeant.

By Nicole Gray • March 4, 2015

AZ board to CEO Soriot: Want that big bonus? Show us the money

After successfully staving off a Pfizer takeover last year, the AZ CEO promised revenues of $45 billion by 2023. But sales are down, and now Soriot's bonus is at stake.

By Nicole Gray • March 3, 2015